Market Overview

UPDATE: Cantor Fitzgerald Initiates Coverage on Bruker

Related BRKR
Earnings Scheduled For February 18, 2014
Bruker Launches ContourSP 3D Optical Microscope
Related BRKR
Bank of America Comments on FDA Approval of Bruker Corporation's MALDI Biotyper CA System
Bruker Granted FDA Clearance to Market the MALDI Biotyper CA System

According to a research report published Thursday, Cantor Fitzgerald has initiated Bruker (NASDAQ: BRKR) with a Buy rating and $16 PT.

In the report, Cantor Fitzgerald said, "Bruker has a highly diversified high-end scientific instrumentation portfolio targeting life science, applied, and industrial markets. In our view, the company is well positioned to capitalize on high-growth market segments over the next several years and deliver above-market top line growth, leveraging internal R&D and strategic tuckins. Additionally, with below sector average margins, Bruker has significant upside for margin expansion in the medium-term."

Bruker closed Wednesday at $13.39.

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Analyst Ratings


Most Popular

Related Articles (BRKR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free